Claudia Finamore
-
- Drug Transport and Resistance Mechanisms 13
- Pharmacology top 10%
-
- HIV/AIDS drug development and treatment 4
-
- Cholesterol and Lipid Metabolism 6
- Pediatric Hepatobiliary Diseases and Treatments 2
-
- Peroxisome Proliferator-Activated Receptors 3
- Natural product bioactivities and synthesis 2
-
- Phytochemistry and Biological Activities 2
-
- Essential Oils and Antimicrobial Activity 2
- Co-authors
- Stefano FiorucciAngela ZampellaAdriana CarinoValentina SepeCarmen FestaSimona De MarinoSilvia MarchianòMaria Chiara Monti
- Cited by
- OncologyHepatologyPharmacology
- Partner nations
- ItalySwitzerlandUnited States
In The Last Decade
Claudia Finamore
23 papers receiving 458 citations
Peers
Comparison fields: 5 of 80
- Oncology 203
- Hepatology 48
- Pharmacology 49
- Infectious Diseases 73
- Computational Theory and Mathematics 44
Countries citing papers authored by Claudia Finamore
This map shows the geographic impact of Claudia Finamore's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Finamore with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Finamore more than expected).
Fields of papers citing papers by Claudia Finamore
This network shows the impact of papers produced by Claudia Finamore. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Finamore. The network helps show where Claudia Finamore may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Claudia Finamore, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 6 | |
| 4 | 2023 | 5 | |
| 5 | 2023 | 7 | |
| 6 | 2023 | 5 | |
| 7 | 2022 | 23 | |
| 8 | 2020 | 9 | |
| 9 | 2020 | 81 | |
| 10 | 2019 | 29 | |
| 11 | 2019 | 3 | |
| 12 | 2019 | 15 | |
| 13 | 2019 | 14 | |
| 14 | 2018 | 31 | |
| 15 | 2017 | 4 | |
| 16 | 2017 | 36 | |
| 17 | 2016 | 13 | |
| 18 | 2016 | 38 | |
| 19 | 2015 | 17 | |
| 20 | 2010 | 32 |
About Claudia Finamore
Claudia Finamore is a scholar working on Oncology, Pharmacology and Hepatology, having authored 24 papers that have together received 464 indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (13 papers), Cholesterol and Lipid Metabolism (6 papers), HIV/AIDS drug development and treatment (4 papers), Peroxisome Proliferator-Activated Receptors (3 papers), Phytochemistry and Biological Activities (2 papers), Pediatric Hepatobiliary Diseases and Treatments (2 papers), Natural product bioactivities and synthesis (2 papers) and Essential Oils and Antimicrobial Activity (2 papers). The work is most often cited by research in Oncology (203 citations), Hepatology (48 citations) and Pharmacology (49 citations). Claudia Finamore has collaborated with scholars based in Italy, Switzerland and United States. Frequent co-authors include Stefano Fiorucci, Angela Zampella, Adriana Carino, Valentina Sepe, Carmen Festa, Simona De Marino, Silvia Marchianò, Maria Chiara Monti, Sabrina Cipriani and Barbara Renga. Their work appears in journals such as Scientific Reports, Journal of Medicinal Chemistry and Molecules.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.